Skip to main content

IDE Clinical Investigation Pathway

The Investigational Device Exemption (IDE) pathway enables the clinical investigation of medical devices that have not yet been cleared or approved by FDA. It is governed by 21 CFR Part 812 and FD&C Act § 520(g).

See IDE — Investigational Device Exemption for the full detailed overview of IDE requirements.

Quick reference — IDE pathway steps​

1. Determine device risk level
       ├── Significant Risk (SR) → FDA IDE application required
       └── Non-Significant Risk (NSR) → Abbreviated IDE (IRB only)
                       ↓
2. Prepare IDE application (SR) or abbreviated IDE (NSR)
                       ↓
3. Submit IDE application to FDA (SR devices)
   FDA review: 30 calendar days
                       ↓
4. Obtain IRB approval (all devices — SR and NSR)
                       ↓
5. Obtain informed consent from all subjects
                       ↓
6. Conduct investigation under IDE conditions
   - Labelled "CAUTION: Investigational device. Limited by Federal law to investigational use."
   - Monitor investigation; report unanticipated adverse effects to FDA
   - Submit IDE progress reports and final study report
                       ↓
7. Use IDE study data in premarket submission
   (510(k), De Novo, or PMA)

IDE and the premarket pathway​

The IDE is the clinical data gateway for PMA submissions. For most Class III PMA devices:

  • Clinical data must come from an IDE-approved pivotal study
  • The pivotal study must be designed with FDA input (via Q-submissions/Pre-Sub meetings)
  • The study must be conducted under GCP with IRB oversight

For 510(k) submissions, clinical data from an IDE study may support substantial equivalence when bench testing alone is insufficient.

IDE supplements​

Once an IDE is approved, changes to the study — including protocol amendments, new sites, or device modifications — require IDE supplements submitted to FDA before implementation.

Official resources​